Join Growin Stock Community!

Aptorum group limitedAPM.US Overview

US StockHealthcare
(No presentation for APM)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

APM AI Insights

APM Overall Performance

APM AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

APM Recent Performance

2.52%

Aptorum group limited

0.05%

Avg of Sector

-0.31%

S&P500

APM PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

APM Key Information

APM Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

APM Profile

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.

Price of APM

APM FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

APM Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.33
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
23.35
PB Ratio
0.28
Price-to-FCF
28.29
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
35.71%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.33
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
23.35
PB Ratio
0.28
Price-to-FCF
28.29
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
35.71%

  • When is APM's latest earnings report released?

    The most recent financial report for Aptorum group limited (APM) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating APM's short-term business performance and financial health. For the latest updates on APM's earnings releases, visit this page regularly.

  • How much debt does APM have?

    As of the end of the reporting period, Aptorum group limited (APM) had total debt of 3.41M, with a debt ratio of 0.19. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does APM have?

    At the end of the period, Aptorum group limited (APM) held Total Cash and Cash Equivalents of 2.76M, accounting for 0.15 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is APM's EPS continuing to grow?

    According to the past four quarterly reports, Aptorum group limited (APM)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.06. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.